Idacta mAb INT-001 represents the promising clinical approach for combating certain hematologic cancers. The immunoglobulin is an distinct process of action, particularly targeting the CD38 antigen, the membrane molecule expressed widely on several hematopoietic tissues. Ongoing patient studies aiming to evaluate the safety and power in patients wi

Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement in targeted cancer treatment. This innovative antibody-drug conjugate combines a monoclonal immunoglobulin specifically targeting HER-2 expressing cells with a potent chemotherapeutic payload, deruxtecan. The mechanism of action involves the antibody's ability